# US 12,180,292 B2 · CD70 binding molecules and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,292 B2
- Document ID: US12180292B2
- Status: Granted
- Kind: B2
- Application number: 17/328,118
- Filed: 2021-05-24
- Published: 2021-09-09
- Granted: 2024-12-31
- Earliest claimed: 2017-02-14
- Assignees: Kite Pharma, Inc.
- Applicants: Kite Pharma, Inc.
- Inventors: Ruben Alvarez Rodriguez; Armen Mardiros
- Web page: https://patentgrep.com/patent/US12180292B2

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4232: {Tumor necrosis factors [TNF] or CD70}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C12N 5/0636: {T lymphocytes}
- C07K 2317/53: Hinge
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

## Claims

### Claim 1

An isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising an antigen binding molecule that specifically binds to CD70, wherein the antigen binding molecule comprises the amino acid sequence of SEQ ID NO: 44.

### Claim 2 (depends on 1)

The polynucleotide of claim 1, wherein the antigen binding molecule is single chained.

### Claim 3 (depends on 1)

The polynucleotide of claim 1, wherein the antigen binding molecule comprises an scFv.

### Claim 4 (depends on 1)

The polynucleotide of claim 1, wherein the CAR or TCR further comprises a transmembrane domain.

### Claim 5 (depends on 4)

The polynucleotide of claim 4, wherein the transmembrane domain is a CD8 alpha transmembrane domain.

### Claim 6 (depends on 1)

The polynucleotide of claim 1, wherein the CAR or TCR further comprises a hinge region between the transmembrane domain and the antigen binding molecule.

### Claim 7 (depends on 6)

The polynucleotide of claim 6, wherein the hinge region is of CD8 alpha.

### Claim 8 (depends on 1)

The polynucleotide of claim 1, wherein the CAR or TCR further comprises a costimulatory region.

### Claim 9

A polynucleotide encoding a CAR or TCR, wherein the polynucleotide comprises the nucleic acid sequence of SEQ ID NOs: 43.

### Claim 10 (depends on 1)

A vector comprising the polynucleotide of claim 1.

### Claim 11 (depends on 1)

A CAR or TCR encoded by the polynucleotide of claim 1.

### Claim 12 (depends on 1)

A cell comprising the polynucleotide of claim 1.

### Claim 13 (depends on 12)

The cell of claim 12, wherein the cell comprises an immune cell.

### Claim 14 (depends on 13)

The cell of claim 13, wherein the cell is a T cell.

### Claim 15 (depends on 1)

A composition comprising the polynucleotide of claim 1.

### Claim 16 (depends on 1)

A method of making a cell expressing a CAR or TCR comprising transducing a cell with the polynucleotide of claim 1 under suitable conditions.

### Claim 17

A CAR or TCR, wherein the CAR or TCR comprises the amino acid sequence of SEQ ID NO: 44, wherein the leader sequence of SEQ ID NO: 44 is absent.